UNSPSC 51285311: Nifuralide

This classification denotes an anti-infective agent and antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98SRO07Q7S. European Medicines Agency schedules Nifuralide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09260MIG. Nifuralide generally arises in the molecular formula C14H13N5O4S.

UNSPSC 51285311 Nifuralide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally describes a specific pharmaceutical compound, but the recent solicitations show state and local governments buying naloxone, medical and first aid supplies for emergency response, generic pharmaceuticals through cooperative purchasing, and exploring direct-to-manufacturer prescription programs—none of which are nifuralide or directly related to it. The mismatch suggests either miscoding in the source data or that nifuralide is purchased so infrequently under this code that recent opportunities reflect broader pharmaceutical procurement rather than the specific commodity.

The recent opportunities span health departments, fire departments, pharmacy benefit programs, and cooperative purchasing consortia across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline; the City of Tampa issued an IFB on March 25, 2026 for medical and first aid supplies for its Fire Department Rescue Division with a $700,000 estimated value and a March 13, 2026 deadline, sheltered for certified Small Local Business Enterprises with a 5% bid discount; the Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The code shows little relevant recent activity tied to nifuralide specifically.